Recommendations from Clinical Practice Guidelines about Managing Patients with Hypertension.

SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada and SAU: Saudi Arabia and NICE (The UK's National Institute for Health and Clinical Excellence). NR: not reported. A: angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blockers (ARB), C: calcium channel blocker (CCB), D: Diuretic. 1And if SBP>150 and or DBP>95- treat. 2If the SBP> or = 140 mm Hg or DBP> or = 90 mm Hg across 5 visits. 3if SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg. 4If, at visit 2 within one month, SBP is > or = 140 mm Hg and/or DBP is > or = 90 mm Hg. 5If SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg with high risk or if SBP 160 mmHg AND/OR DBP 100 mmHg regardless of risk. 6NICE CPG favored A for those below 55 years and C, D, for those aged 55 years or older and for black patients. 7Yes if SBP>10 mmHg above target. 8Recommended in at least certain high risk groups. 9Recommended for those with atherosclerotic renal artery stenosis only. 10No target level stated. 11A1c<6.5 mmol/L. 12A1c between 6.5–7% in patients with HTN, DM and nephropathy. 13Referred to previous guideline version. 14Every 3–6 months; 15Every 3 months for high risk patients and every 6 months for low risk patients; 16Every 3 months for the first year then 6-monthly thereafter; 17Once a year. 18For pheochromocytoma cases only.